In a groundbreaking head-to-head trial, Eli Lilly's drug Zepbound has been found to be superior to Novo Nordisk's popular medication Wegovy across multiple weight-loss metrics. The trial, a first of its kind in comparing these two widely-used medicines, showcased significant advantages for Zepbound, providing Eli Lilly with a powerful edge as it aims to expand insurance coverage in the burgeoning obesity drug market projected to exceed $150 billion annually in the coming years.
According to Lilly, Zepbound demonstrated notable results, with nearly 25% more participants achieving over 15% weight loss compared to those on Wegovy. Additionally, Zepbound led to an average reduction of 18.4 centimeters in waist circumference, surpassing Wegovy's average reduction of 13 cm among trial participants.
In response, Novo Nordisk acknowledged the trial data but highlighted that the weight-loss outcomes for Wegovy were lower than those reported in a similar 2021 trial with a comparable dose. The company emphasized that Wegovy, as a GLP-1 agonist, holds unique benefits as the only medication in its class approved to prevent major cardiovascular events such as heart attacks. Novo Nordisk also noted promising results from a recent trial involving a higher dose of semaglutide, the active ingredient in Wegovy.
Previous reports from Lilly in December had already indicated significant weight-loss superiority for Zepbound compared to Wegovy, with a 47% greater weight loss observed. The comprehensive data from the study, which was unveiled by Lilly in a press release and presented at the European Congress on Obesity, reinforced Zepbound's effectiveness in tackling obesity.
These findings emerge in the wake of CVS Health's recent decision to exclude Zepbound from certain lists of covered medications, opting instead to prioritize Wegovy. While Zepbound employs a dual mechanism of action by mimicking two gut hormones to promote weight loss, Wegovy operates through a single mode of action.
The U.S. approvals for both Zepbound and Wegovy were based on separate trials, with Lilly's drug leading to more than 22% weight loss after 72 weeks and Wegovy resulting in a 15% weight loss after 68 weeks. Looking ahead, the head-to-head trial results signal a significant advancement in understanding the efficacy of these medications in the fight against obesity, offering valuable insights for healthcare providers and patients seeking effective weight-loss solutions.